Health Innovation Next Generation Payment & Pricing Models

Project Information

HI-PRIX

Grant agreement ID: 101095593

DOI

10.3030/101095593

Project closed

EC signature date 11 November 2022

Start date 1 January 2023

End date 31 December 2025

Funded under

• Health

Total cost

€ 3 962 457,50

EU contribution

€ 3 962 457,50

Coordinated by

UNIVERSITA COMMERCIALE LUIGI BOCCONI
Italy

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (13)

Recommendations on pricing principles for multi-indication products and conditions for their successful implementation
A novel dynamic pricing model that links to clinical benefit: impact and acceptability for stakeholders
Strength of incentive mechanisms and policy recommendations to incentivize pharmaceutical innovation in key areas of need
Equity implications of including indirect medical costs and environmental impacts in economic evaluations informing pricing and reimbursement
Policy guide on the role of cost-effectiveness and budget impact analyses (including indirect medical costs and environmental impacts) in pricing and reimbursement decisions in different European decision contexts
Outline of the equity-issues mitigation strategies identified, and related potential obstacles
Stakeholders judgement on barriers and enablers of novel payment/pricing schemes
Effectiveness and equity implications of selected pharmaceutical innovation policies and incentive mechanisms
Guidance (Handbook) on estimations (ranges) of cost elements along the value chain for demanding detailed information in price negotiations
Report on the overall performance of a selection of equity-issues mitigation strategies and recommendations
Set of recommendations for using the public investment in the negotiation/HTA process and pilot example how price can be different if public investment is considered
Policy recommendations about successful and flexible implementation of the different schemes to promote access to high-quality affordable innovative health technologies
Report on contextualization of simulation results and synthesis of findings with regard to the current use and the regulatory measures, levers and barriers to the widespread practical implementation of the respective payment schemes and their impact on lo

Report on contextualization of simulation results and synthesis of findings with regard to the current use and the regulatory measures, levers and barriers to the widespread practical implementation of the respective payment schemes and their impact on long-term competition in health technology markets

Demonstrators, pilots, prototypes (2)

Assessment of transferability and generalizability of results and development of a toolkit for decision-makers
Impact of applying the new payment schemes to (a) a primary care and (b) an integrated care setting

Websites, patent fillings, videos etc. (1)

Launch of project website

Publications

Peer reviewed articles (18)

Early and accelerated access programs for medical devices in the European Union: mapping regulatory derogations and national schemes

Author(s): Baptiste Haon, Mira Hartmann, Sanae Akodad, Hilde Stevens, Lise Rochaix
Published in: Frontiers in Medical Technology, Issue 8, 2026, ISSN 2673-3129
Publisher: Frontiers Media SA
DOI: 10.3389/FMEDT.2026.1729631

Journal of Pharmaceutical Policy and Practice

Author(s): Louise Schmidt; Ozren Sehic; Ursula Theuretzbacher; Daniel Fabian; Claudia Wild
Published in: Journal of Pharmaceutical Policy and Practice, 2025, ISSN 2052-3211
Publisher: Taylor & Francis
DOI: 10.1080/20523211.2024.2449045

AIHTA-Framework erleichtert Identifikation öffentlicher Beiträge zur Entwicklung von Innovationen im Gesundheitswesen

Author(s): Ozren Sehic
Published in: QUALITAS, 2024, ISSN 2730-7298
Publisher: Springer Nature
DOI: 10.1007/S43831-024-0187-6

Mechanisms Considering Public Investment in Pricing and Reimbursement Decisions of Medicines and Other Health Technologies: A Scoping Review

Author(s): Mario García-Díaz; Zuzana Špacírová; Leticia García-Mochón; Jaime Espín
Published in: Applied Health Economics and Health Policy, 2025, ISSN 2509-4254
Publisher: Springer Nature
DOI: 10.1007/S40258-025-00994-5

Frontiers in Psychiatry

Author(s): Sanae Akodad, Michel Goldman, Hilde Stevens
Published in: Frontiers in Medicine, Issue 12, 2025, ISSN 1664-0640
Publisher: Frontiers Research Foundation
DOI: 10.3389/FMED.2025.1642882

Applied Health Economics and Health Policy

Author(s): Ludovico Cavallaro; Vittoria Ardito; Michael Drummond; Oriana Ciani
Published in: Applied Health Economics and Health Policy, 2025, ISSN 1175-5652
Publisher: Open Mind Journals
DOI: 10.1007/S40258-025-00963-Y

Health Policy

Author(s): Claudia Wild; Ozren Sehic; Louise Schmidt; Daniel Fabian
Published in: Health Policy, 2025, ISSN 0168-8510
Publisher: Elsevier Ltd.
DOI: 10.1016/J.HEALTHPOL.2024.105235

Frontiers in Pharmacology

Author(s): García Díaz, Mario; Epstein, David Mark; Espín, Jaime
Published in: Frontiers in Pharmacology, 2025, ISSN 1663-9812
Publisher: Frontiers Media SA
DOI: 10.3389/FPHAR.2025.1670845

Social Science and Medicine

Author(s): Arianna Gentilini; Marisa Miraldo
Published in: Social Science & Medicine, 2023, ISSN 0277-9536
Publisher: Pergamon Press Ltd.
DOI: 10.1016/J.SOCSCIMED.2023.116332

Orphan medical devices: addressing the regulatory and access gaps in the EU and US

Author(s): Sanae Akodad; Baptiste Haon; Lise Rochaix; Hilde Stevens
Published in: Frontiers in Public Health, 2026, ISSN 2296-2565
Publisher: Frontiers Media SA
DOI: 10.3389/FPUBH.2025.1729821

Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-Offs

Author(s): Mario García-Díaz; Jorge Mestre-Ferrándiz; Jaime Espín
Published in: PharmacoEconomics - Open, 2026, ISSN 2509-4262
Publisher: Springer Nature
DOI: 10.1007/S41669-025-00628-5

PharmacoEconomics

Author(s): Vittoria Ardito; Oriana Ciani; Michael Drummond
Published in: PharmacoEconomics, 2024, ISSN 1179-2027
Publisher: Adis International Ltd.
DOI: 10.1007/S40273-024-01435-2

Applied Health Economics and Health Policy

Author(s): Ardito, Vittoria; Banks, Helen; Tarricone, Rosanna
Published in: Applied Health Economics and Health Policy, 2025, ISSN 1175-5652
Publisher: Springer Nature
DOI: 10.1007/S40258-025-01010-6

Journal of Pharmaceutical Policy and Practice

Author(s): Daniel Fabian; Ozren Sehic; Claudia Wild
Published in: The origins of Novo Nordisk and Novartis products: piloting a framework to identify the public contributions, 2025, ISSN 2052-3211
Publisher: Taylor & Francis Group
DOI: 10.1080/20523211.2025.2534919

Medicare Negotiations Could Fuel, Not Stifle, Innovation.

Author(s): Chuanzi Yue, Marisa Miraldo
Published in: Health Affairs Forefront, 2025, ISSN 3070-667X
Publisher: Health Affairs Publishing, LLC
DOI: 10.1377/FOREFRONT.20250116.482319

A Framework for Considering the Role of the Public Sector in R&D of Health Technology

Author(s): Juan Carlos Rejon-Parrilla; David Epstein; Jorge Mestre-Ferrandiz; Jaime Espin
Published in: Pharmaceutical Medicine, 2025, ISSN 0306-3747
Publisher: Springer Nature
DOI: 10.1007/S40290-025-00576-9

Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review

Author(s): ARDITO, VITTORIA; CAVALLARO, LUDOVICO; DRUMMOND, MICHAEL; CIANI, ORIANA
Published in: PharmacoEconomics - Open, 2024, ISSN 2509-4254
Publisher: Springer Nature
DOI: 10.1007/S41669-024-00496-5

ESG Performance, Debt Financing, and R&D Output: Evidence From the Healthcare Sector

Author(s): Sarmad Ali; Oriana Ciani; Simone Ghislandi
Published in: Business Strategy and the Environment, ISSN 1099-0836
Publisher: John Wiley & Sons Ltd
DOI: 10.1002/BSE.70522